The Latest Breaking News from Novo Nordisk

Ozempic, a once-weekly semaglutide injection, has grown in popularity for its weight loss side effects

Novo’s Ozepmic and Wegovy drugs have altered the mission of the 100-year-old Danish pharma firm best known—until now—for insulin.

Stomach paralysis risk raises concerns over popular weight loss and diabetes drugs

Ozempic and Saxenda among drugs being reviewed after five reports of suspected adverse reactions in patients

The FDA has received reports of stomach paralysis among patients taking Ozempic and Wegovy

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

Artificial intelligence stocks including chipmaker Marvell Technology (MRVL), Arista Networks (ANET) and Synopsys (SNPS), which has launched AI-based chip-design tools, lead this weekend's watch list of five stocks near buy points. In addition to MRVL, ANET and SNPS stock, weight-loss drug leader Novo Nordisk (NVO) and Heico (HEI), a military…

Do pharmaceutical companies have influence over your doctor's prescription pad? It's relatively easy to check—but you shouldn't have to, experts say.

Concerns of weight loss and Type 1 diabetes are fueling the rise of our choice for this week's option position in shares of Novo Nordisk.

Tesla and Netflix were big losers in a deeply divided market Thursday, but this chip giant was the most important.

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.